<DOC>
	<DOCNO>NCT02434861</DOCNO>
	<brief_summary>The objective Open Label Study evaluate effect Rolapitant IV solution , metabolite , pharmacokinetics ( PK ) P-gp substrate ( digoxin ) , BCRP substrate ( sulfasalazine ) , multiple cytochrome P450 ( CYP ) probe substrates healthy adult population .</brief_summary>
	<brief_title>An Open Label , Single Dose , Three Part Study Assess Effects Rolapitant ( 2 mg/mL IV Solution ) Pharmacokinetics Digoxin ; Sulfasalazine ; Cooperstown Cocktail ( Midazolam , Omeprazole , Warfarin , Caffeine , Dextromethorphan Healthy Subjects</brief_title>
	<detailed_description>- Part A compare PK oral digoxin alone combination IV infusion rolapitant . - Part B compare PK oral dose sulfasalazine alone PK oral dose sulfasalazine combination IV infusion rolapitant - Part C compare PK oral dose Cooperstown Cocktail ( midazolam , omeprazole , warfarin , caffeine , dextromethorphan ) alone give combination IV infusion rolapitant .</detailed_description>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>8- ( ( 1- ( 3,5-bis ( trifluoromethyl ) phenyl ) ethoxy ) methyl ) -8-phenyl-1,7-diazaspiro ( 4,5 ) decan-2-one</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Main Subjects must healthy male female age 18 55 year ( inclusive ) Female subject ( childbearing potential ) must negative pregnancy test Screening Day 1 Female subject childbearing potential must agree use accepted method birth control ( exclude hormonal birth control method ) Visit 1 continue use study least 30 day final dose Subjects must body mass index ( BMI ) 18.5 32.0 kg/m2 ( inclusive ) weight ≥50 kg Screening Subjects must capable understanding informed consent risk benefit study explain ; subject must able sign write informed consent willing comply protocol requirement Subjects must general good health determine Investigator base prestudy medical surgical history , physical examination [ PE ] , clinical laboratory test Main Subjects participate another investigational study within 30 day 5 halflives test drug 's biologic activity , whichever longer , time first study dose Subjects history relevant allergy ( include asthma , food , drug allergy ) determine Investigator Subjects significant blood loss , donate receive ≥1 unit ( 450 mL ) blood , within 30 day first study dose Subjects history hypersensitivity rolapitant IV excipients participate previous rolapitant study within 6 month prior administration first dose study drug ( Day 1 ) Subjects poor venous access and/or tolerate venipuncture Subjects history significant complication anxiety associate IV administration medication , opinion Investigator , could make subject Subjects history hypersensitivity sulfasalazine ( Part B ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>